Magnesium Disorders: The Forgotten Electrolyte

Executive Summary

Magnesium disorders are frequently underrecognized. Hypomagnesemia affects 2–15% of hospitalized patients and up to 65% of ICU patients. Magnesium serves as cofactor for over 300 enzymatic reactions and plays crucial roles in cellular energy metabolism, protein synthesis, and ion channel function. Understanding its relationships with potassium and the PTH-calcium axis proves essential for managing complex electrolyte disorders.

Physiologic Role and Homeostasis

Fourth most abundant cation in the body, second most prevalent intracellular cation (after potassium). Total body Mg: ~25 g (1,000 mmol) — 99% intracellular (60% bone, 39% soft tissues, only 1% in ECF). This distribution explains why serum levels may not reflect total body stores.

Normal serum Mg: 1.8–2.4 mg/dL (0.75–1.0 mmol/L). Kidneys filter ~2,400 mg daily with 95% reabsorbed:

• 20% proximal tubule
• 60% thick ascending limb of Henle (via claudin-16 and claudin-19)
• 10% distal convoluted tubule (via TRPM6 channels)

The Mg-ATP complex is the physiologically active form of ATP. Magnesium modulates Na-K-ATPase, calcium channels, cardiac conduction, neuromuscular function, and vascular tone.

Hypomagnesemia: Pathophysiology, Diagnosis, and Management

Nutritional and Absorptive Disorders

Chronic Alcohol Use Disorder

One of the most common causes, affecting an estimated 30% of hospitalized alcoholic patients. Multiple mechanisms:

• Direct intestinal epithelial damage and altered TRPM6/TRPM7 transporter expression
• Alcohol-induced GI inflammation reducing absorptive surface area
• Poor dietary intake + increased renal losses from alcohol-induced diuresis
• Alcohol withdrawal significantly increases Mg requirements (enhanced sympathetic activity)

Chronic diarrhea (secretory > osmotic), inflammatory bowel disease, short bowel syndrome, chronic pancreatitis. Post-surgical states: extensive small bowel resection, bariatric surgery (Roux-en-Y, biliopancreatic diversion).

Refeeding syndrome risk: rapid carbohydrate administration increases cellular Mg demands while depleted stores cannot meet requirements, potentially precipitating severe hypomagnesemia.

Renal Magnesium Wasting

• Gitelman syndrome: NCCT gene mutations → hypomagnesemia, hypokalemia, hypocalciuria
• Bartter syndrome variants: Mg wasting with volume depletion
• Loop diuretics: Inhibit Mg reabsorption in thick ascending limb
• Thiazide diuretics: Affect DCT; chronic use produces a “Gitelman phenocopy”
• Other medications: Aminoglycosides, calcineurin inhibitors, cisplatin, cetuximab

Endocrine and Metabolic Causes

• Diabetes mellitus: Osmotic diuresis from glucosuria + diabetic nephropathy + insulin resistance effects
• Hyperaldosteronism: Enhanced distal tubule flow rates → increased renal Mg excretion
• Hyperthyroidism: Increased renal Mg clearance + reduced intestinal absorption

Table 1: Causes of Hypomagnesemia by Category

Clinical Manifestations and Diagnostic Approach

Clinical Manifestations

Often asymptomatic until Mg <1.2 mg/dL (0.5 mmol/L). Early: fatigue, weakness, irritability, muscle cramps. Progressive: Chvostek and Trousseau signs, muscle fasciculations (facial muscles are early/specific). Severe: tetany, seizures, altered mental status.

Cardiovascular Complications

• Atrial and ventricular arrhythmias; digitalis toxicity enhanced
• Torsades de pointes: Most serious complication, especially with concurrent hypokalemia or prolonged QT
• Coronary artery spasm, increased peripheral vascular resistance

Laboratory Assessment

Serum Mg limitations: Up to 30% of total body Mg may be lost before serum levels decrease.

Magnesium tolerance test: 0.2 mmol/kg IV MgSO4, measure 24h urine. Retention >50% indicates deficiency (gold standard but limited clinical utility).

Fractional excretion of Mg: FE_Mg = (U_Mg × S_Cr) / (0.7 × S_Mg × U_Cr) × 100. In hypomagnesemia: >2% = renal wasting; <2% = extrarenal losses or inadequate intake.

Table 3: Diagnostic Workup for Hypomagnesemia

Treatment Strategies

Oral Magnesium Supplementation

Dosing: 400–800 mg elemental Mg daily, divided into 2–3 doses. Treatment duration: weeks to months depending on etiology.

Parenteral Magnesium Therapy

Acute Severe Hypomagnesemia

1–2 g (4–8 mmol) MgSO4 in 50–100 mL NS IV over 1–2 hours, then 6 g (24 mmol) over 24 hours by continuous infusion. Monitor serum levels every 6–8 hours.

Chronic Parenteral Therapy

Weekly or twice-weekly infusions of 2–4 g MgSO4 for patients with ongoing losses or malabsorption.

Hypermagnesemia: Recognition and Management

Etiology

Rarely occurs with normal renal function. CKD stages 4–5 (eGFR <30) significantly impairs Mg elimination. Common sources: excessive IV MgSO4 (eclampsia treatment), Mg-containing antacids/laxatives in renal impairment, Epsom salt ingestion.

Table 2: Causes of Hypermagnesemia

Threshold Effects and Clinical Correlation

Management of Hypermagnesemia

Severe Symptomatic

1. IV calcium: 1–2 g calcium chloride or 2–3 g calcium gluconate for functional antagonism. Effects appear within minutes but are temporary.
2. Enhanced elimination: NS + furosemide 40–80 mg IV (adequate renal function). Promotes Mg excretion.
3. Hemodialysis: For severe hyperMg with renal failure. Clearance rates approach 100 mL/min. CRRT for hemodynamically unstable patients.
4. Supportive care: Mechanical ventilation if respiratory depression; vasopressors for severe hypotension.

Special Clinical Considerations

Mg-Containing Laxatives in CKD

Preferred laxatives in CKD: PEG-based (MiraLAX), docusate sodium, senna/bisacodyl cautiously, lubiprostone, linaclotide. Avoid all Mg-containing products (milk of magnesia, Mg citrate, Epsom salts).

Proton Pump Inhibitors and Hypomagnesemia

Incidence: 5–10% of long-term users. Mechanism: impaired intestinal Mg absorption via TRPM6/TRPM7 channel inhibition + altered gastric pH affecting Mg solubility. Dose-dependent and duration-related (typically months to years before manifestation).

Suspect in long-term PPI users with neuromuscular symptoms, especially with concurrent hypoK and hypoCa resistant to replacement. Consider H2 receptor antagonists as alternatives.

Diuretics and Magnesium Homeostasis

Loop Diuretics

Inhibit NKCC2 in the thick ascending limb (where 60% of Mg is reabsorbed). Furosemide has greatest Mg-wasting potential. Losses increase proportionally with dose; patients on >80 mg daily furosemide equivalent are at particular risk.

Thiazide Diuretics

Affect NCCT in the DCT. Chlorthalidone and indapamide (longer half-lives) may produce more sustained Mg losses. Chronic use produces a “Gitelman syndrome phenocopy”: hypoMg, hypoK, hypocalciuria.

Monitoring: Baseline Mg, then at 1–2 weeks, then every 3–6 months. More frequent with dose changes or addition of other Mg-depleting drugs.

Potassium-sparing diuretics (amiloride, spironolactone) may partially mitigate Mg losses but do not completely prevent depletion.

Electrolyte Interrelationships: Mg, K, and the Ca-PTH Axis

Magnesium-Potassium Interactions

One of the most clinically significant electrolyte interactions. Approximately 60% of hypoMg patients have concurrent hypoK.

• Mg deficiency reduces Na-K-ATPase activity → cellular K losses + impaired renal K reabsorption
• Mg depletion enhances K secretion in the collecting duct (increased K channel activity + altered mineralocorticoid sensitivity)

Magnesium-Calcium-PTH Relationships

• Mild-moderate hypoMg: Stimulates PTH release (secondary hyperparathyroidism)
• Severe hypoMg (<1.0 mg/dL): Paradoxically suppresses PTH secretion (impaired synthesis and release)
• PTH resistance: HypoMg reduces target organ responsiveness to PTH in both bone and kidney → functional hypoparathyroidism
• Vitamin D metabolism: Mg is cofactor for 25-OH-D-1alpha-hydroxylase → deficiency impairs activation of 1,25(OH)2D3

References and Suggested Reading

1. de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95(1):1-46. PMID: 25540137
2. Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in hospitalized patients: prevalence and prognostic importance. Mayo Clin Proc. 2015;90(9):1202-1213. PMID: 26250725
3. Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia. JAMA. 1990;263(22):3063-3064. PMID: 2342219
4. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649-2652. PMID: 17804670
5. Hoorn EJ, Zietse R. Disorders of calcium and magnesium balance: a physiology-based approach. Pediatr Nephrol. 2013;28(8):1195-1206. PMID: 23142866
6. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999;10(7):1616-1622. PMID: 10405219
7. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405-413. PMID: 22762246
8. Saris NE, Mervaala E, Karppanen H, et al. Magnesium: an update on physiological, clinical and analytical aspects. Clin Chim Acta. 2000;294(1-2):1-26. PMID: 10727669
9. Van Laecke S. Hypomagnesemia and hypermagnesemia. Acta Clin Belg. 2019;74(1):41-47. PMID: 30220246
10. Topf JM, Murray PT. Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord. 2003;4(2):195-206. PMID: 12766548

Also on this topic

The same subject at other levels of depth.

• Student handout: Magnesium Disorders: Student Handout